Lupus erythematosus syndrome induced by drugs

Drug-Induced and Iatrogenic Respiratory Disease

Volumn , Issue , 2010, Pages 297-307

  Rubin, Robert L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923357071     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Morrow JD, Schroeder HA, Perry HM. Studies on the control of hypertension by hyphex. II: Toxic reactions and side effects. Circulation 1953;8: 829-39.
2. Ladd AT. Procainamide-induced lupus erythematosus. New Engl J Med 1962;267: 1357-8.
3. Mongey AB, Sim E, Risch A, Hess E. Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide. J Rheumatol 1999;26: 1721-6.
4. Alarcon-Segovia D. Drug-induced lupus syndrome. Mayo Clin Proc 1967;44: 664-81.
5. Wallace DJ, Dubois EL. Drugs that exacerbate and induce systemic lupus erythematosus. In: Wallace DJ, Dubois EL (eds) Dubois’ Lupus Erythematosus, pp 450-69. Philadelphia, PA: Lea & Febiger, 1987.
6. Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilol 1945;51: 190-2.
7. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus. J Rheumatol 1992;19: 265-9.
8. Ben Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Safety 2000;23: 143-64.
9. Sovijarvi AR, Lemola M, Stenius B, Idanpaan-Heikkila J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977;58: 41-50.
10. Petz LD. Autoimmune and drug-induced immune hemolytic anemia. In: Rose NR, et al. (eds) Manual of Clinical Laboratory Immunology, pp 325-43. Washington, DC: American Society for Microbiology, 1992.
11. Mackay IR, Cowling DC, Hurley TH. Drug-induced autoimmune disease: hemolytic anemia and lupus cells after treatment with methyldopa. Med J Aust 1968;2: 1047-50.
12. Nordstrom DM, West SG, Rubin RL. Methyldopa-induced systemic lupus erythematosus. Arthritis Rheum 1989;32: 205-8.
13. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestions by cytokine therapy. Arthritis Rheum 2000;43: 1431-42.
14. Lee SL, Rivero I, Siegel M. Activation of systemic lupus erythematosus by drugs. Arch Intern Med 1966;117: 620-6.
15. Fries JF, Holman HR. Systemic lupus erythematosus: a clinical analysis. In: Problems in Internal Medicine. Philadelphia: Saunders, 1975.
16. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43: 405-13.
17. Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. New Engl J Med 1988; 318: 1431-6.
18. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J 1984;289: 410-12.
19. Mansilla-Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J 1982;284: 936-9.
20. Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999;159: 493-7.
21. Condemi JJ, Moore-Jones D, Vaughan JH, Perry HM. Antinuclear antibodies following hydralazine toxicity. New Engl J Med 1967;276: 486-90.
22. Perry HM. Late toxicity of hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 1973;54: 58-72.
23. Jiang X, Khursigara G, Rubin RL. Transformation of lupusinducing drugs to cytotoxic products by activated neutrophils. Science 1994;266: 810-13.
24. Perry HMJ, Tan EM, Carmody S, Sakomoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970;76: 114-25.
25. Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ Lupus Erythematosus, 7th edn, pp 870-900. Philadelphia: Lippincott Williams & Wilkins, 2007.
26. Diri E, Tello W, Ratnoff WD, Nugent K. Infliximab-induced SLE-like syndrome involving the lung and pleura. Lupus 2007;16: 764-6.
27. Cohen MG, Kevat S, Prowse MV, Ahern MJ. Two distinct quinidine induced rheumatic syndromes. Ann Intern Med 1988;108: 369-71.
28. Dunphy J, Oliver M, Rands AL, Lovell CR, McHugh NJ. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000;142: 461-7.
29. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003;12: 409-12.
30. Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. Can J Gastroenterol 1999; 13: 159-62.
31. Mitchell JA, Batchelor JR, Chapel H, Spiers CN, Sim E. Erythrocyte complement receptor type 1 (CR1) expression and circulating immune complex (CIC) levels in hydralazineinduced SLE. Clin Exp Immunol 1987;68: 446-56.
32. Becker M, Klajman A, Moalem T, Yaretzky A, Ben-Efraim S. Circulating immune complexes in sera from patients receiving procainamide. Clin Immunol Immunopathol 1979;12: 220-7.
33. Brandslund I, Ibsen HHW, Klitgaard NA, et al. Plasma concentrations of complement split product C3d and immune complexes after procainamide induced production of antinuclear antibodies. Acta Med Scand 1986;220: 431-5.
34. Rubin RL, Nusinow SR, Johnson AD, et al. Serological changes during induction of lupus-like disease by procainamide. Am J Med 1986;80: 999-1002.
35. Rubin RL, Tang F-L, Chan EKL, et al. IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren’s syndrome, and drug-induced autoimmunity. J Immunol 1986;137: 2528-34.
36. Vivino FB, Schumacher HRJ. Synovial fluid characteristics and the lupus erythematosus cell phenomenon in drug-induced lupus. Arthritis Rheum 1989;32: 560-8.
37. Fritzler M, Ryan P, Kinsella TD. Clinical features of systemic lupus erythematosus patients with antihistone antibodies. J Rheumatol 1982;9: 46-51.
38. Klajman A, Farkas R, Ben-Efraim S. Complement-fixing activity of antinuclear antibodies induced by procainamide treatment. Isr J Med Sci 1973;9: 627-30.
39. Kanayama Y, Peebles C, Tan EM, Curd JG. Complement activating abilities of defined antinuclear antibodies. Arthritis Rheum 1986;29: 748-54.
40. Rubin RL, Teodorescu M, Beutner EH, Plunkett RW. Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus. Lupus 2004;13: 249-56.
41. Hieronymus T, Grotsch P, Blank N, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000;43: 1994-2004.
42. Ablin J, Verbovetski I, Trahtemberg U, Metzger S, Mevorach D. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 2005;10: 1009-18.
43. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signalregulated kinase pathway signaling. Arthritis Rheum 2003;48: 746-56.
44. Adams LE, Roberts SM, Donovan-Brand R, Zimmer H, Hess EV. Study of procainamide hapten-specific antibodies in rabbits and humans. Int J Immunopharmacol 1993;15: 887-97.
45. Kammüller ME, Thomas C, De Bakker JM, Bloksma N, Seinen W. The popliteal lymph node assay in mice to screen for the immune disregulation potential of chemicals: a preliminary study. Int J Immunopharmacol 1989;11: 293-300.
46. Kubicka-Muranyi M, Goebels R, Goebel C, Uetrecht J, Gleichmann E. T-lymphocytes ignore procainamide, but respond to its reactive metabolites in peritoneal cells: demonstration by the adoptive transfer popliteal lymph node assay. Toxicol Appl Pharmacol 1993;122: 88-94.
47. Katsutani N, Shionoya H. Popliteal lymph node enlargement induced by procainamide. Int J Immunopharmacol 1992; 14: 681-6.
48. von Greyerz S, Burkhart C, Pichler WJ. Molecular basis of drug recognition by specific T-cell receptors. Intern Arch Allergy Immunol 2000;119: 173-80.
49. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998;19: 133-41.
50. Rubin RL, Uetrecht JP, Jones JE. Cytotoxicity of oxidative metabolites of procainamide. J Pharmacol Exp Ther 1987;242: 833-41.
51. Wheeler JF, Lunte CE, Heineman WR, Adams L, Hess EV. Rapid communications: electrochemical determination of N-oxidized procainamide metabolites and functional assessment of effects on murine cells in vitro. Proc Soc Exp Biol Med 1988;188: 381-6.
52. Adams LE, Sanders CE, Budinsky RA, et al. Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus. J Lab Clin Med 1989;113: 482-92.
53. Adams LE, Roberts SM, Carter JM, et al. Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines. Int J Immunopharmacol 1990;12: 809-19.
54. Hess DA, Sisson ME, Suria H, et al. Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(1) cells by the hydroxylamine of sulfamethoxazole. Faseb J 1999;13: 1688-98.
55. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000;58: 207-16.
56. Tschen AC, Rieder MJ, Oyewumi LK, Freeman DJ. The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 1999;65: 526-32.
57. Gardner I, Leeder JS, Chin T, Zahid N, Uetrecht JP. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol 1998;53: 999-1008.
58. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997;283: 1375-82.
59. Ayer LM, Edworthy SM, Fritzler MJ. Effect of procainamide and hydralazine on poly (ADP-ribosylation) in cell lines. Lupus 1993;2: 167-72.
60. Quddus J, Johnson KJ, Gavalchin J, et al. Treating activated CD41 T-cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to induce a lupus-like disease in syngeneic mice. J Clin Invest 1993;92: 38-52.
61. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanisms of drug-induced lupus. I: Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995;154: 3025-35.
62. Yung R, Powers D, Johnson K, et al. Mechanisms of druginduced lupus. II: T-cells overexpressing lymphocyte functionassociated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97: 2866-71.
63. Scheinbart LS, Johnson MA, Gross LA, Edelstein SR, Richardson BC. Procainamide inhibits DNA methyltransferase in a human T-cell line. J Rheumatol 1991;18: 530-4.
64. Oelke K, Lu Q, Richardson D, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004;50: 1850-60.
65. Gleichmann E, Pals ST, Rolink AG, Radaskiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 1984;5: 324-32.
66. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance: a murine model of drug-induced lupus. J Clin Invest 1997;99: 1888-96.
67. Kretz-Rommel A, Rubin RL. Persistence of autoreactive T cell drive in required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus. J Immunol 1999;162: 813-20.
68. Kretz-Rommel A, Rubin RL. A metabolite of the lupusinducing drug procainamide prevents anergy induction in T cell clones. J Immunol 1997;158: 4465-70.
69. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nature Med 2000; 6: 298-305.
70. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396: 690-5.
71. Rubin RL, Salomon DR, Guerrero RS. Thymus function in drug-induced lupus. Lupus 2001;10: 795-801.
72. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7.
73. Rubin RL, Burlingame RW, Arnott JE, et al. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995;154: 2483-93.
74. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94: 184-92.
75. Prockop LD. Myotonia, procaine amide, and lupus-like syndrome. Arch Neurol 1966;14: 326-30.
76. Solinger AM. Drug-related lupus: clinical and etiological considerations. Rheum Dis Clin North Am 1988;14: 187-202.